Literature DB >> 18227349

Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis.

Maria Rosa Lidonnici1, Francesca Corradini, Todd Waldron, Timothy P Bender, Bruno Calabretta.   

Abstract

The c-Myb gene encodes a transcription factor required for proliferation and survival of normal myeloid progenitors and leukemic blast cells. Targeting of c-Myb by antisense oligodeoxynucleotides has suggested that myeloid leukemia blasts (including chronic myelogenous leukemia [CML]-blast crisis cells) rely on c-Myb expression more than normal progenitors, but a genetic approach to assess the requirement of c-Myb by p210(BCR/ABL)-transformed hematopoietic progenitors has not been taken. We show here that loss of a c-Myb allele had modest effects (20%-28% decrease) on colony formation of nontransduced progenitors, while the effect on p210(BCR/ABL)-expressing Lin(-) Sca-1(+) and Lin(-) Sca-1(+)Kit(+) cells was more pronounced (50%-80% decrease). Using a model of CML-blast crisis, mice (n = 14) injected with p210(BCR/ABL)-transduced p53(-/-)c-Myb(w/w) marrow cells developed leukemia rapidly and had a median survival of 26 days, while only 67% of mice (n = 12) injected with p210(BCR/ABL)-transduced p53(-/-)c-Myb(w/d) marrow cells died of leukemia with a median survival of 96 days. p210(BCR/ABL)-transduced c-Myb(w/w) and c-Myb(w/d) marrow progenitors expressed similar levels of the c-Myb-regulated genes c-Myc and cyclin B1, while those of Bcl-2 were reduced. However, ectopic Bcl-2 expression did not enhance colony formation of p210(BCR/ABL)-transduced c-Myb(w/d) Lin(-)Sca-1(+)Kit(+) cells. Together, these studies support the requirement of c-Myb for p210(BCR/ABL)-dependent leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18227349      PMCID: PMC2343605          DOI: 10.1182/blood-2007-08-105072

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

Authors:  T Skorski; A Bellacosa; M Nieborowska-Skorska; M Majewski; R Martinez; J K Choi; R Trotta; P Wlodarski; D Perrotti; T O Chan; M A Wasik; P N Tsichlis; B Calabretta
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

2.  Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b.

Authors:  E Kroon; J Krosl; U Thorsteinsdottir; S Baban; A M Buchberg; G Sauvageau
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

3.  Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants.

Authors:  Francesca Corradini; Vincenzo Cesi; Viviana Bartella; Elisabetta Pani; Rita Bussolari; Olivia Candini; Bruno Calabretta
Journal:  J Biol Chem       Date:  2005-05-31       Impact factor: 5.157

4.  Truncated c-Myb expression in the human leukemia cell line TK-6.

Authors:  A Tomita; T Watanabe; H Kosugi; H Ohashi; T Uchida; T Kinoshita; S Mizutani; T Hotta; T Murate; M Seto; H Saito
Journal:  Leukemia       Date:  1998-09       Impact factor: 11.528

5.  Myb and ets proteins are candidate regulators of c-kit expression in human hematopoietic cells.

Authors:  M Z Ratajczak; D Perrotti; P Melotti; M Powzaniuk; B Calabretta; K Onodera; D A Kregenow; B Machalinski; A M Gewirtz
Journal:  Blood       Date:  1998-03-15       Impact factor: 22.113

6.  c-Myb is critical for B cell development and maintenance of follicular B cells.

Authors:  Matthew D Thomas; Christopher S Kremer; Kodi S Ravichandran; Klaus Rajewsky; Timothy P Bender
Journal:  Immunity       Date:  2005-09       Impact factor: 31.745

7.  c-Myb is essential for early T cell development.

Authors:  R D Allen; T P Bender; G Siu
Journal:  Genes Dev       Date:  1999-05-01       Impact factor: 11.361

8.  Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase.

Authors:  T Skorski; M Nieborowska-Skorska; P Wlodarski; D Perrotti; R Martinez; M A Wasik; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

9.  v-Myb of E26 leukemia virus up-regulates bcl-2 and suppresses apoptosis in myeloid cells.

Authors:  J Frampton; T Ramqvist; T Graf
Journal:  Genes Dev       Date:  1996-11-01       Impact factor: 11.361

10.  Resistance to apoptosis in CTLL-2 cells constitutively expressing c-Myb is associated with induction of BCL-2 expression and Myb-dependent regulation of bcl-2 promoter activity.

Authors:  P Salomoni; D Perrotti; R Martinez; C Franceschi; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

View more
  29 in total

1.  Targeting acute myeloid leukemia by drug-induced c-MYB degradation.

Authors:  V Walf-Vorderwülbecke; K Pearce; T Brooks; M Hubank; M M van den Heuvel-Eibrink; C M Zwaan; S Adams; D Edwards; J Bartram; S Samarasinghe; P Ancliff; A Khwaja; N Goulden; G Williams; J de Boer; O Williams
Journal:  Leukemia       Date:  2017-11-01       Impact factor: 11.528

Review 2.  Polycomb group proteins: navigators of lineage pathways led astray in cancer.

Authors:  Adrian P Bracken; Kristian Helin
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

3.  Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance.

Authors:  Sanjeev K Srivastava; Arun Bhardwaj; Seema Singh; Sumit Arora; Steven McClellan; William E Grizzle; Eddie Reed; Ajay P Singh
Journal:  Carcinogenesis       Date:  2012-03-19       Impact factor: 4.944

4.  Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia.

Authors:  Marco De Dominici; Patrizia Porazzi; Angela Rachele Soliera; Samanta A Mariani; Sankar Addya; Paolo Fortina; Luke F Peterson; Orietta Spinelli; Alessandro Rambaldi; Giovanni Martinelli; Anna Ferrari; Ilaria Iacobucci; Bruno Calabretta
Journal:  Cancer Res       Date:  2017-12-12       Impact factor: 12.701

5.  The histone acetyltransferase TIP60 interacts with c-Myb and inactivates its transcriptional activity in human leukemia.

Authors:  Huiwu Zhao; Shenghao Jin; Alan M Gewirtz
Journal:  J Biol Chem       Date:  2011-11-21       Impact factor: 5.157

6.  Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.

Authors:  Stéphane Flamant; William Ritchie; Joëlle Guilhot; Jeff Holst; Marie-Laure Bonnet; Jean-Claude Chomel; François Guilhot; Ali G Turhan; John E J Rasko
Journal:  Haematologica       Date:  2010-05-11       Impact factor: 9.941

7.  c-myb hyperactivity leads to myeloid and lymphoid malignancies in zebrafish.

Authors:  W Liu; M Wu; Z Huang; J Lian; J Chen; T Wang; A Y H Leung; Y Liao; Z Zhang; Q Liu; K Yen; S Lin; L I Zon; Z Wen; Y Zhang; W Zhang
Journal:  Leukemia       Date:  2016-06-14       Impact factor: 11.528

8.  Regulation of cyst wall protein promoters by Myb2 in Giardia lamblia.

Authors:  Yu-Chang Huang; Li-Hsin Su; Gilbert A Lee; Pei-Wei Chiu; Chao-Cheng Cho; Jeng-You Wu; Chin-Hung Sun
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

9.  c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.

Authors:  Shenghao Jin; Huiwu Zhao; Yan Yi; Yuji Nakata; Anna Kalota; Alan M Gewirtz
Journal:  J Clin Invest       Date:  2010-01-19       Impact factor: 14.808

10.  Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice.

Authors:  Richard A Steinman; Qiong Yang; Maura Gasparetto; Lisa J Robinson; Xiaoping Liu; Diana E Lenzner; Jingzhou Hou; Clayton Smith; Qingde Wang
Journal:  Int J Cancer       Date:  2012-10-17       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.